TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
2024年8月15日 - 8:00PM
TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology
company committed to more effectively treating cancer using RNA
therapeutics, today announced initiation of its Phase 1
multicenter, open-label, clinical study of its lead therapeutic
candidate, TTX-MC138.
Two clinical trial sites have been activated
with patient enrollment expected to begin during the current
quarter. TransCode may activate a total of up to five clinical
trial sites, all of which are expected to be activated this
quarter.
The Phase 1 clinical trial is designed to
generate critical data to support evaluation of the safety of
TTX-MC138 in patients with a variety of metastatic solid cancer. It
may provide early evidence of TTX-MC138 clinical activity. The
trial comprises an initial dose-escalation phase followed by a
dose-expansion phase. The primary objective of the dose-escalation
phase is to evaluate the safety and tolerability of escalating dose
levels of TTX-MC138. In the dose-expansion phase, the safety,
tolerability and anti-tumor activity of TTX-MC138 will be further
evaluated in certain tumor types selected based on preliminary
results from the dose-escalation phase.
“We are thrilled to have garnered such high
interest in TTX-MC138 from eminent oncologists working in some of
the most respected clinical trial sites in the country,” commented
Sue Duggan, Senior Vice President, Operations, at TransCode.
“Advancing breakthrough RNA therapeutics science in the clinic is
our primary goal as a biotechnology company at the cusp of
innovative technology,” added Duggan.
Active and recruiting sites can be found
at: https://clinicaltrials.gov/study/NCT06260774?spons=transcode&rank=1
About TransCode
Therapeutics
TransCode Therapeutics is a clinical-stage
oncology company focused on treating metastatic disease. The
company is committed to defeating cancer through the intelligent
design and effective delivery of RNA therapeutics based on its
proprietary TTX nanoparticle platform. The company’s lead
therapeutic candidate, TTX-MC138, is focused on treating metastatic
tumors which overexpress microRNA-10b, a unique, well-documented
biomarker of metastasis. In addition, TransCode is developing a
portfolio of first-in-class RNA therapeutic candidates designed to
overcome the challenges of RNA delivery and thus unlock therapeutic
access to a variety of novel genetic targets that could be relevant
to treating a variety of cancers.
Forward-Looking Statements
This release contains “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including, without limitation, statements
concerning the therapeutic potential of TransCode’s TTX-MC138 and
the timing, conduct and results of the planned clinical trial. Any
forward-looking statements in this press release are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk associated
with drug discovery and development; the risk that the results of
our clinical trials will not be consistent with our pre-clinical
studies or expectations or with previous clinical trials; risks
associated with the timing and outcome of TransCode’s planned
regulatory submissions; risks associated with TransCode’s conduct
of clinical trials; risks associated with obtaining, maintaining
and protecting intellectual property; risks associated with
TransCode’s ability to enforce its patents against infringers and
defend its patent portfolio against challenges from third parties;
risks of competition from other companies developing products for
similar uses; risks associated with TransCode’s financial condition
and its need to obtain additional funding to support its business
activities, including TransCode’s ability to continue as a going
concern; risks associated with TransCode’s dependence on third
parties; and risks associated with geopolitical events and
pandemics, including the COVID-19 coronavirus. For a discussion of
these and other risks and uncertainties, and other important
factors, any of which could cause TransCode’s actual results to
differ from those contained in or implied by the forward-looking
statements, see the section entitled “Risk Factors” in TransCode’s
Annual Report on Form 10-K for the year ended December 31, 2023, as
well as discussions of potential risks, uncertainties and other
important factors in any subsequent TransCode filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release; TransCode undertakes no
duty to update this information unless required by law.
For more information, please
contact:
TransCode Therapeutics, Inc.Tania Montgomery-Hammon, VP of
Business Developmenttania.montgomery@transcodetherapeutics.com
TransCode Therapeutics (NASDAQ:RNAZ)
過去 株価チャート
から 9 2024 まで 10 2024
TransCode Therapeutics (NASDAQ:RNAZ)
過去 株価チャート
から 10 2023 まで 10 2024